PD-L1-Ausdruck durch IHC
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BIO-PDL1-EXPRESSION |
|---|---|
| Art | Biomarker |
| Aliase | B7-H1CD274PD-L1PD-L1-AusdruckЕкспресія PD-L1 (ІГХ) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Erkrankungen | DIS-BREAST |
| Quellen | SRC-NCCN-BCELL-2025 |
Biomarker-Fakten
| Biomarker-Typ | protein_expression_ihc |
|---|---|
| Messung | VerfahrenIHC bei FFPE-Biopsie (22C3, SP142, SP263 Klone — assazspezifische Bewertung) EinheitenTumoranteils-Score (TPS) % ODER kombinierter positiver Score (CPS) |
| Verwandte Biomarker | None declared |
Anmerkungen
Cross-disease relevance — checkpoint inhibitor response marker: - **Classical Hodgkin Lymphoma**: 9p24 amplification → universal PD-L1 over-expression → dramatic response to nivolumab / pembrolizumab (~70% ORR in r/r). Approved for r/r cHL after autoSCT + brentuximab failure. - **Primary Mediastinal Large B-Cell Lymphoma (PMBCL)**: similar 9p24 + universal PD-L1 → checkpoint-responsive. Pembrolizumab approved r/r PMBCL. - **EBV+ neoplasms** (EBV+ DLBCL elderly, NK/T, PTLD): variable PD-L1 + checkpoint-response in subset. - **Mediastinal Gray Zone Lymphoma**: PD-L1+ subset. - Most other DLBCL / NHL: PD-L1 expression variable, response rates lower; not standard. Algorithm impact: future 2L+ pembrolizumab/nivolumab routing for cHL r/r post-autoSCT. PMBCL future scope (Tier 2 disease).
Verwendet von
Biomarker
BIO-PDL1-22C3-CLONE- PD-L1 IHC — Dako 22C3 PharmDx-KlonBIO-PDL1-28-8-CLONE- PD-L1 IHC — Dako 28-8 PharmDx-KlonBIO-PDL1-CPS- PD-L1 kombinierter positiver Score (CPS)BIO-PDL1-SP142-CLONE- PD-L1 IHC — Ventana SP142 KlonBIO-PDL1-SP263-CLONE- PD-L1 IHC — Ventana SP263 Klon
Kapitel des Handbuchs
HB-MELANOMA-METASTATIC-1L- Metastatisches Melanom: BRAF / IO first-line Argumentation
Warnhinweis
RF-BREAST-HIGH-RISK-BIOLOGY- Germlin- oder somatische BRCA1/2-Mutation, PIK3CA-Mutation, ESR1-Mutation, HER2-Amplifikation,...